Literature DB >> 24461561

Ionic liquid mediated synthesis of mono- and bis-spirooxindole-hexahydropyrrolidines as cholinesterase inhibitors and their molecular docking studies.

Yalda Kia1, Hasnah Osman2, Raju Suresh Kumar3, Alireza Basiri4, Vikneswaran Murugaiyah4.   

Abstract

One pot, three-component reaction of 1-acryloyl-3,5-bisarylmethylidenepiperidin-4-ones with isatin and sarcosine in molar ratios of 1:1:1 and 1:2:2 furnished to mono- and bis-spiropyrrolidine heterocyclic hybrids comprising functionalized piperidine, pyrrolidine and oxindole structural motifs. Both mono and bis-spiropyrrolidines displayed good inhibitory activity against acetylcholinesterase (AChE) with IC₅₀ values of 2.36-9.43 μM. For butyrylcholinesterase (BChE), mono-cycloadducts in series 8 with IC₅₀ values of lower than 10 μM displayed better inhibitory activities than their bis-cycloadduct analogs in series 9 with IC₅₀ values of 7.44-19.12 μM. The cycloadducts 9j and 8e were found to be the most potent AChE and BChE inhibitors with IC₅₀ values of 2.35 and 3.21 μM, respectively. Compound 9j was found to be competitive inhibitor of AChE while compound 8e was a mixed-mode inhibitor of BChE with calculated Ki values of 2.01 and 6.76 μM, respectively. Molecular docking on Torpedo californica AChE and human BChE showed good correlation between IC₅₀ values and free binding energy values of the synthesized compounds docked into the active site of the enzymes.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  1,3-Dipolar cycloaddition; AChE; Alzheimer’s disease; BChE; Enzyme kinetic study and molecular docking; Spiropyrrolidines

Mesh:

Substances:

Year:  2014        PMID: 24461561     DOI: 10.1016/j.bmc.2014.01.002

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  6 in total

1.  Synthesis and molecular modeling studies of cholinesterase inhibitor dispiro[indoline-3,2'-pyrrolidine-3',3''-pyrrolidines].

Authors:  M Adel Youssef; Siva S Panda; Riham A El-Shiekh; ElSayed M Shalaby; Dalia R Aboshouk; Walid Fayad; Nehmedo G Fawzy; Adel S Girgis
Journal:  RSC Adv       Date:  2020-06-08       Impact factor: 4.036

2.  Synthesis of a New Class of Spirooxindole-Benzo[b]Thiophene-Based Molecules as Acetylcholinesterase Inhibitors.

Authors:  Assem Barakat; Saeed Alshahrani; Abdullah Mohammed Al-Majid; M Ali; Mezna Saleh Altowyan; Mohammad Shahidul Islam; Abdullah Saleh Alamary; Sajda Ashraf; Zaheer Ul-Haq
Journal:  Molecules       Date:  2020-10-13       Impact factor: 4.411

3.  Bifunctional thiosquaramide catalyzed asymmetric reduction of dihydro-β-carbolines and enantioselective synthesis of (-)-coerulescine and (-)-horsfiline by oxidative rearrangement.

Authors:  Manda Sathish; Fabiane M Nachtigall; Leonardo S Santos
Journal:  RSC Adv       Date:  2020-10-21       Impact factor: 4.036

4.  Highly functionalized pyrrolidine analogues: stereoselective synthesis and caspase-dependent apoptotic activity.

Authors:  Raju Suresh Kumar; Abdulrahman I Almansour; Natarajan Arumugam; Faruq Mohammad; Waleed Shihan Alshahrani; Kotresha D; Mohammad Altaf; Mohammad Azam; J Carlos Menéndez
Journal:  RSC Adv       Date:  2018-12-10       Impact factor: 4.036

5.  Development of spiro-3-indolin-2-one containing compounds of antiproliferative and anti-SARS-CoV-2 properties.

Authors:  Nehmedo G Fawazy; Siva S Panda; Ahmed Mostafa; Benson M Kariuki; Mohamed S Bekheit; Yassmin Moatasim; Omnia Kutkat; Walid Fayad; May A El-Manawaty; Ahmed A F Soliman; Riham A El-Shiekh; Aladdin M Srour; Reham F Barghash; Adel S Girgis
Journal:  Sci Rep       Date:  2022-08-16       Impact factor: 4.996

6.  A facile ionic liquid promoted synthesis, cholinesterase inhibitory activity and molecular modeling study of novel highly functionalized spiropyrrolidines.

Authors:  Abdulrahman I Almansour; Raju Suresh Kumar; Natarajan Arumugam; Alireza Basiri; Yalda Kia; Mohamed Ashraf Ali; Mehvish Farooq; Vikneswaran Murugaiyah
Journal:  Molecules       Date:  2015-01-29       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.